Personalized Circulating Tumor Deoxyribonucleic Acid (CtDNA) Fingerprint Panels Global Market Report 2026

The personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market size has grown rapidly in recent years. It will grow from $1.27 billion in 2025 to $1.48 billion in 2026 at a compound annual growth rate (CAGR) of 16.7%. The growth in the historic period can be attributed to increasing cancer prevalence, advancements in next-generation sequencing, rising demand for non-invasive diagnostics, growing research in genomic biomarkers, regulatory support for precision medicine.

The personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market size is expected to see rapid growth in the next few years. It will grow to $2.78 billion in 2030 at a compound annual growth rate (CAGR) of 17%. The growth in the forecast period can be attributed to adoption of ai-powered genomic analysis, expansion of personalized oncology programs, integration with hospital information systems, increasing investments in ctDNA panels, demand for real-time treatment monitoring. Major trends in the forecast period include personalized ctdna assay development, longitudinal cancer monitoring, integration with clinical decision support systems, non-invasive disease tracking, ai-driven mutation analysis.

The increasing prevalence of cancer is expected to drive the growth of the personalized circulating tumor DNA fingerprint panels market in the coming years. Cancer includes a range of diseases characterized by the uncontrolled growth of abnormal cells that can invade nearby tissues and metastasize to other parts of the body. The prevalence of cancer is rising due to longer life expectancy, enhanced early detection, and advances in treatment that allow patients to survive longer with the disease. Personalized circulating tumor DNA fingerprint panels aid cancer treatment by enabling early detection, continuous monitoring, and precise management of tumor progression, thereby improving survival outcomes and guiding targeted therapeutic strategies. For example, in October 2025, according to the American Cancer Society, a US-based nonprofit organization focused on cancer research and advocacy, there are approximately 18.6 million cancer survivors in the U.S., representing just over 5% of the population, with projections estimating growth to 22 million by 2035. Hence, the rising prevalence of cancer is propelling the expansion of the personalized circulating tumor DNA fingerprint panels market.

Key companies operating in the personalized circulating tumor DNA (ctDNA) fingerprint panels market are focusing on developing ultra-sensitive, tumor-informed genome-based assays to improve early cancer detection, monitor treatment response, and detect molecular residual disease (MRD) with higher precision. Ultra-sensitive, tumor-informed, genome-based assays are advanced molecular diagnostics that identify and track patient-specific tumor mutations to detect extremely low levels of circulating tumor DNA (ctDNA) in blood. For example, in April 2025, Natera Inc., a US-based molecular diagnostics company, announced the broad clinical launch of its ultra-sensitive Signatera Genome MRD test. The test leverages whole-genome sequencing (WGS) to design highly individualized ctDNA fingerprint panels tailored to each patient’s tumor profile, significantly increasing the number of tracked tumor variants and enhancing detection sensitivity at ultra-low ctDNA levels. This advancement strengthens MRD monitoring capabilities across multiple cancer types and supports earlier intervention and more informed treatment decision-making.

In December 2025, Natera, Inc., a US-based provider of cell-free DNA testing and precision medicine solutions, acquired Foresight Diagnostics, Inc. for an undisclosed sum. Through this acquisition, Natera intends to enhance its personalized ctDNA molecular residual disease testing capabilities, expand into lymphoma-related applications, and integrate Foresight's ultrasensitive phased variant technology into its Signatera platform. Foresight Diagnostics, Inc. is a US-based cancer diagnostics company and CLIA-registered laboratory that provides circulating tumor DNA-based molecular residual disease testing leveraging patented phased-seq technology.

Major companies operating in the personalized circulating tumor deoxyribonucleic acid (ctdna) fingerprint panels market are F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Laboratory Corporation of America Holdings, Agilent Technologies Inc., Illumina Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc., Myriad Genetics Inc., NeoGenomics Laboratories Inc., Guardant Health Inc., Pacific Biosciences of California Inc., Burning Rock Biotech Limited, Personalis Inc., Biodesix Inc., OneCell Diagnostics Pvt. Ltd., CD Genomics, Creative Biolabs Inc., Predicine Inc., BioCreatrix Pte. Ltd., OncoDNA SA, Lucence Diagnostics Pte Ltd., Singlera Genomics Inc., Nonacus Ltd.

North America was the largest region in the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market consists of revenues earned by entities by providing services such as clinical data interpretation, laboratory testing services, and reporting and data management. The market value includes the value of related goods sold by the service provider or included within the service offering. The personalized circulating tumor DNA (ctDNA) fingerprint panels market also includes sales of sequencing reagents, PCR reagents, microfluidic cartridges, and benchtop sequencers. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Personalized circulating tumor DNA (ctDNA) fingerprint panels are tailored molecular diagnostic assays designed to detect and monitor tumor-specific genetic changes in circulating tumor DNA fragments found in blood samples. These panels are developed by analyzing a patient’s tumor tissue to identify unique mutation patterns and creating a custom sequencing assay to track minimal residual disease, recurrence, or treatment response with high sensitivity. They employ advanced next-generation sequencing and sophisticated bioinformatics to enable precise, non-invasive longitudinal cancer monitoring.

The key product types of personalized circulating tumor deoxyribonucleic acid (DNA) fingerprint panels include single gene panels, multi-gene panels, and comprehensive genomic panels. Single gene panels are designed to detect specific tumor-related mutations in circulating tumor DNA to support precision oncology and disease monitoring. These panels are applied across cancer types including lung cancer, breast cancer, colorectal cancer, pancreatic cancer, gastrointestinal cancer, and hematological malignancies. They are developed using technologies such as next-generation sequencing, polymerase chain reaction-based methods, and other techniques. Applications include oncology, non-invasive prenatal testing, transplantation, and other areas, serving hospitals and clinics, diagnostic laboratories, research institutes, and other end users.

Tariffs have affected the personalized ctDNA fingerprint panels market by raising costs for importing sequencing instruments, reagents, and bioinformatics software. This has primarily impacted product types like multi-gene and comprehensive genomic panels, especially in North America and Europe, which rely heavily on imported advanced equipment. While tariffs increase production expenses and may slow adoption, they are also encouraging domestic manufacturing, local sourcing of reagents, and innovation in cost-effective sequencing solutions, ultimately supporting market resilience and diversification.

The personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market research report is one of a series of new reports that provides personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market statistics, including personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels industry global market size, regional shares, competitors with a personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market share, detailed personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market segments, market trends and opportunities, and any further data you may need to thrive in the personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels industry. This personalized circulating tumor deoxyribonucleic acid (ctDNA) fingerprint panels market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.